USPTO serial 79254181
LUXCEPTAR
Reviewed by CopyMark Law Group
Reg. 5917334Status 709
- Filing date
- Status date
- Registration date
- Nov 26, 2019
- Examiner
- LATTUCA, FRANK J
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with LUXCEPTAR?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Kiadis Pharma Netherlands B.V.
NL
Kiadis Pharma Intellectual Property B.V.
NL
Other trademarks owned by Kiadis Pharma Intellectual Property B.V.
Kiadis Pharma Intellectual Property B.V.
NL
Other trademarks owned by Kiadis Pharma Intellectual Property B.V.
Kiadis Pharma Intellectual Property B.V.
NL
Other trademarks owned by Kiadis Pharma Intellectual Property B.V.
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medical and veterinary preparations and articles for the immune modulation; pharmaceuticals and natural remedies namely, natural remedy preparations for the immune modulation; medicines for the immune modulation; pharmaceuticals for the immune modulation and for the prophylaxis of immune system related diseases and disorders; pharmaceutical preparations, namely, preparations for immune modulation and for prophylaxis of immune system related diseases and disorders; pharmaceutical drugs namely, preparations for immune modulation and for prophylaxis of immune system related diseases and disorders; pharmaceutical implants namely, implantable intravenously drug delivery devices sold filled with pharmaceutical preparations for the immune modulation; pharmaceutical preparations for activating cellular function; cellular function activating agents for medical purposes; clinical medical reagents; cultures of microorganisms for medical use; medical preparations namely, pharmaceuticals and biological compounds to support the growth of stem cells; surgical implants comprised of living tissues grown from stem cells; medical diagnostic reagents; stem cells for research purposes; stem cells for medical purposes; reagents for blood grouping for medical purposes; anti-cancer drugs namely pharmaceuticals for the treatment of cancer; compounds namely, anti-cancer preparations for treating cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer | SECTION 71 - CANCELLED | — |
| 044 | Human healthcare services; medical services; pharmaceutical consultancy services; medical diagnostic testing, monitoring, and reporting services; medical treatment services namely, medical diagnosis and treatment for the immune modulation and prophylaxis of immune system related diseases and disorders; surgical treatment services; medical services relating to the removal, treatment and processing of stem cells; analysis of human serum for medical treatment; analysis of human tissues for medical treatment | SECTION 71 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by Kiadis Pharma Netherlands B.V.
- Other trademarks owned by Kiadis Pharma Intellectual Property B.V.
- Other trademarks owned by Kiadis Pharma Intellectual Property B.V.
- Other trademarks owned by Kiadis Pharma Intellectual Property B.V.
- Other trademarks in Class 005
- Other trademarks in Class 044
- Similar marks named LUXCEPTAR
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 12, 2026 | C71T | CANCELLED SECTION 71 | — |
| Aug 9, 2024 | CHLD | CHANGE OF OWNER RECEIVED FROM IB | — |
| Jun 19, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 10, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| Apr 3, 2020 | FINO | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| Mar 16, 2020 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| Mar 16, 2020 | FIMP | FINAL DISPOSITION PROCESSED | — |
| Feb 26, 2020 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Nov 26, 2019 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Sep 10, 2019 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Aug 21, 2019 | NPUB | NOTICE OF PUBLICATION | — |
| Aug 8, 2019 | ALIE | ASSIGNED TO LIE | — |
| Jul 29, 2019 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jul 26, 2019 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jul 26, 2019 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jul 26, 2019 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 12, 2019 | RFNT | REFUSAL PROCESSED BY IB | — |
| Mar 28, 2019 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Mar 28, 2019 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Mar 21, 2019 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Mar 20, 2019 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Mar 19, 2019 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 17, 2019 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 17, 2019 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 14, 2019 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |